ORLA combined with telerehabilitation in patients with subacute poststroke aphasia: A randomized controlled trial
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
BACKGROUND: Oral reading for language in aphasia (ORLA) therapy coupled with telerehabilitation (TR) is a promising adjunct to therapy for aphasia. METHODS:This single-center, randomized, single-blind, 6-month trial aimed to evaluate whether ORLA combined with TR demonstrates comparable efficacy to conventional ORLA offline rehabilitation for improving comprehensive language ability in subacute aphasia patients, while assessing longitudinal treatment effects. Enrolled patients were randomized 1:1:1 into: Group A (medium-high intensity ORLA TR）：Group B (low intensity ORLA TR）Group C (medium-high intensity ORLA offline). All groups received a 6-month, 90-hour intervention comprising three treatment phases. The primary outcome was change in Aphasia Quotient (AQ) at baseline and 4 weeks, 3 months, and 6 months post-treatment. Secondary outcomes included quality of life and language subscale scores at the same timepoints. RESULTS: A total of 42 participants were analyzed,Group A demonstrated a non-significant mean difference of -0.62 (95% CI, -5.00 to 6.23; P=0.83) in AQ compared to Group C.A statistically significant difference in the Stroke Aphasia Quality of Life-39 Scale (SAQOL-39) scores between Group A and Group C (mean difference: -8.19; 95% CI [-12.39, -3.99]; P < 0.001). Group A vs. Group C: No statistically significant differences were observed in any of the aforementioned language subskills between Group A and Group C (P>0.05 for all comparisons). CONCLUSIONS: ORLA combined with TR demonstrated comparable efficacy to conventional ORLA offline rehabilitation, serving as a viable alternative for home-based speech rehabilitation in subacute aphasia patients. This TR approach improved both comprehensive language ability and quality of life, with sustained treatment effects over time. First registration date: August 18, 2023 (retrospective registration, Chinese Clinical Trial Registry number: ChiCTR2300074870).
